Crescent Biopharma, Inc.
CBIO
$17.14
$0.513.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.88M | 11.88M | 10.84M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.88M | 11.88M | 10.84M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 11.88M | 11.88M | 10.84M | -- | -- |
| SG&A Expenses | 29.46M | 29.66M | 25.39M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 182.12M | 175.02M | 163.48M | -- | -- |
| Operating Income | -170.24M | -163.14M | -152.63M | -- | -- |
| Income Before Tax | -163.12M | -160.08M | -151.94M | -- | -- |
| Income Tax Expenses | 2.00M | 2.00M | 2.00M | -- | -- |
| Earnings from Continuing Operations | -165.12 | -162.08 | -153.94 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.12M | -162.08M | -153.94M | -- | -- |
| EBIT | -170.24M | -163.14M | -152.63M | -- | -- |
| EBITDA | -170.03M | -162.99M | -138.32M | -- | -- |
| EPS Basic | -6.72 | -10.90 | -29.83 | -- | -- |
| Normalized Basic EPS | -4.18 | -6.76 | -18.59 | -- | -- |
| EPS Diluted | -6.72 | -10.90 | -29.83 | -- | -- |
| Normalized Diluted EPS | -4.18 | -6.76 | -18.59 | -- | -- |
| Average Basic Shares Outstanding | 109.20M | 80.20M | 47.69M | -- | -- |
| Average Diluted Shares Outstanding | 109.20M | 80.20M | 47.69M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |